Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 11/12/2025 GMT			5-day change	1st Jan Change
2,046.00 ^DKK	+2.74%		-0.78%	+37.09%

12-11	Genmab A/S - Special Call
12-09	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT

Transcript : Genmab A/S Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 03

Published on 01/14/2025

S&P Capital IQ

Presenter Speech
James Gordon (Analysts)

Good afternoon. I'm James Gordon, JPMorgan European pharma biotech analyst. And it's my pleasure to introduce the Genmab presentation this afternoon. And we're

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

12-11	Genmab A/S - Special Call
12-09	BillionToOne Q3 Swings to Profit, Revenue Rises; Shares Fall After Hours	MT
12-09	Genmab shares encouraging early-stage data on epcoritamab for RT patients	RE
12-09	Genmab Presents Promising Data for Epcoritamab in Richter's Transformation	FW
12-08	Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms	MT
12-08	Genmab announces data from multiple clinical trials	RE
12-08	Genmab presents phase 3 data from EPCORE FL-1 trial	RE
12-08	Genmab Reports Strong Phase 3 Data for Epkincly Combination	FW
12-08	JP Morgan Raises Genmab Price Target to 2,050 Danish Kroner (from 1,650), Maintains Neutral Rating - BN	FW
12-04	Genmab A/S Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 09:45 AM
12-04	Genmab Closes $2.5 Billion Senior Notes Offering	MT
12-03	Genmab A/S and Genmab Finance LLC Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes	CI
12-02	European Equities Close Mixed in Tuesday Trading; Euro Area Inflation Rises 2.2% in November	MT
12-02	Genmab, Pfizer's Cervical Cancer Drug Gets UK Regulatory Nod	MT
12-02	Genmab's Cervical Cancer Drug Gets UK Regulatory Approval	MT
11-22	Genmab A/S Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 12:00 PM
11-19	FDA Approves Genmab's Combination Therapy for Follicular Lymphoma	FW
11-19	Genmab Unit Prices $2.5 Billion Senior Notes Offering	MT
11-18	Genmab announces pricing of private offering of senior secured notes and senior unsecured notes	RE
11-18	Genmab Reports FDA Approval for Epkinly in Follicular Lymphoma	MT
11-18	Genmab Secures US Approval for Follicular Lymphoma Combo Therapy	MT
11-18	Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
11-14	Kepler Cheuvreux Kicks Off Genmab Coverage at Hold	MT
11-11	Fitch Assigns First-time Rating to Genmab with Stable Outlook	MT
11-10	Genmab Plans $2.5 Billion Notes Offering, Launches Syndication of $2 Billion Term Loan	MT